Devonian Health Group (GSD) Q4 2024 earnings summary

Executive summary

• Fourth quarter revenues reached $9 million, marking a 749% year-over-year increase, driven by the launch of DEXLANSOPRAZOLE by subsidiary Altius.

• Annual revenues totaled $17.8 million, up 660% year over year, reflecting significant growth in distribution activities.

• Fourth quarter net income was $1.081 million ($0.007 per share), reversing a loss from the prior year; annual net loss narrowed to $1.225 million ($0.008 per share) from $4.6 million ($0.03 per share) last year.

• Continued progress in pre-clinical studies and preparations for phase II/III clinical trials for Thykamine™ in pediatric atopic dermatitis.

Financial highlights

• Distribution revenue for Q4 was $9 million, up 749% year over year, and $17.82 million for the fiscal year, up 660% year over year.

• Q4 net income was $1.081 million ($0.007 per share), compared to a loss of $0.863 million ($0.01 per share) in the prior year.

• Annual net loss was $1.225 million ($0.008 per share), improved from a $4.6 million loss ($0.03 per share) the previous year.

Outlook and guidance

• Management highlighted a breakout year with strong financial support from Altius' product launch and ongoing scientific development for Thykamine™.

• Continued focus on advancing Thykamine™ clinical programs and expanding the product pipeline.